Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Alcon Research287 enrolled

Overview

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

287

Conditions

Allergic Conjunctivitis

Interventions

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%DRUG

Olopatadine Hydrochloride Ophthalmic Solution VehicleDRUG

Inactive ingredients used as a placebo comparator

Eligibility

Sex: ALLMin age: 10 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model Exclusion Criteria: * Under 10 years of age

Outcomes

Primary Outcomes

Daily ocular itching and redness scores

Time frame: Up to Day 14

Secondary Outcomes

Percentage of patients with daily ocular itching and redness scores of 0

Time frame: Up to Day 14

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.